查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736525

全球禽流感疫苗市场－按类型、株类型、应用、地区、预测分類的市场规模

Global Avian Influenza Vaccines Market Size By Type (Combination Vaccines, Inactivated Vaccines), By Strain-Type (H5 strain, H7 strain), By Application (Goose, Duck, Chicken), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

禽流感疫苗市场规模及预测

2024 年禽流感疫苗市场规模为 1.4014 亿美元，预计到 2032 年将达到 1.9854 亿美元，预测期内（2026-2032 年）的复合年增长率为 4.45%。

该报告对全球禽流感疫苗的市场份额、产量和销售进行了深入分析。

推动全球禽流感疫苗市场发展的因素

禽流感疫苗市场的驱动因素可能受到多种因素的影响。这些因素包括：

禽流感疫情加剧 推动市场发展的主要因素之一是全球禽类和鸟类中禽流感疫情的增加。此类疫情对人类和动物族群构成威胁，因此对有效疫苗的需求也随之增加。

政府措施和法规：为了遏制禽流感的蔓延，各国政府和国际组织实施了严格的立法和疫苗宣传活动。这些项目为疫苗生产商创造了有利的环境，并促进了市场扩张。

家禽养殖业的扩张：禽流感疫苗的需求受到家禽养殖业扩张的影响，尤其是在新兴经济体。由于鸡群数量的增加，农民加大了对疫苗接种的投入，以保护他们的牲畜，这支撑了市场的成长。

疫苗技术发展：随着疫苗技术的不断发展，包括更有效、更有效率的疫苗製剂、给药方法和佐剂的开发，禽流感疫苗的安全性和有效性正在不断提高。这些技术进步有可能吸引生产者和消费者，促进市场扩张。

认知与教育：市场扩张的一个关键驱动力是提高消费者、兽医和家禽养殖户对疫苗接种在预防禽流感疫情中价值的认识。疫苗接种率的提高得益于教育活动和资讯传播计划。

全球化与贸易：随着禽类产品在国际贸易中的流通，禽流感在各国之间传播的可能性很高。为了降低风险并确保贸易安全，许多国家已强制要求进出口禽类产品进行疫苗接种，导致全球对禽流感疫苗的需求增加。

限制全球禽流感疫苗市场的因素

禽流感疫苗市场面临许多限制和挑战，其中包括：

疫苗研发和生产成本高：禽流感疫苗研发和生产成本高昂，限制了市场扩张。这些成本使得疫苗对製造商和接种者来说都负担不起，尤其是在偏远地区。

农村地区疫苗取得受限：禽流感疫苗的分发和管理因取得问题而受到阻碍，尤其是在医疗设施不足的农村和偏远地区。这些限制导致疫苗接种率低，并加剧了这些地区疫情的持续爆发。

疫苗安全性和有效性担忧：儘管疫苗技术不断进步，但人们对禽流感疫苗的安全性和有效性仍然存在疑虑。疫苗效力、病毒株突变以及潜在的副作用都可能威胁大众对疫苗宣传活动的信心，并阻碍市场扩张。

监管障碍和核准程序：禽流感疫苗繁琐的监管规范和核准程序会延迟新产品的上市，并增加製造商的开发成本。这些法律障碍阻碍了新的竞争者进入市场，从而降低了创新和竞争。

全球经济不确定性：禽流感疫苗的需求可能受到政府医疗预算和消费者购买习惯变化、经济不稳定和国际市场波动的影响。经济疲软可能导致农业和医疗保健部门的预算削减，从而阻碍潜在的市场扩张。

抗原漂移和疫苗抗药性风险：由于抗原漂移，禽流感病毒的日益增多威胁着疫苗的有效性。对现有疫苗产生抗药性的病毒株的出现可能会降低疫苗的有效性，并且开发新的製剂和方法需要时间和成本。

目录

第一章：全球禽流感疫苗市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球禽流感疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球禽流感疫苗市场（按类型）

  • 概述
  • 联合疫苗
  • 灭活疫苗
  • 活病毒疫苗

6. 全球禽流感疫苗市场（依病毒株型）

  • 概述
  • H5株
  • H7株
  • H9株

7. 全球禽流感疫苗市场（依应用）

  • 概述
  • 鹅
  • 鸭子
  • 鸡
  • 其他的

8. 全球禽流感疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

9. 全球禽流感疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • QianYuanHao Biological Corporation Limited
  • Merial
  • Harbin Veterinary Research Institute（HVRI）
  • CEVA
  • Elanco
  • FATRO SpA
  • Zoetis, Inc.
  • Ringpu Bio-Technology Co., Ltd
  • Merck Animal Health（a subsidiary of Merck & Co. Inc.）
  • Boehringer Ingelheim GmbH

第十一章 附录

  • 相关调查
简介目录
Product Code: 37464

Avian Influenza Vaccines Market Size And Forecast

Avian Influenza Vaccines Market size was valued at USD 140.14 Million in 2024 and is projected to reach USD 198.54 Million by 2032, growing at a CAGR of 4.45% during the forecasted period 2026 to 2032.

Growing disease prevalence, rising demand for poultry for consumption, an increase in the number of outbreaks, and ongoing research for the development of efficient vaccinations for disease prevention are some of the important drivers driving market expansion. The Global Avian Influenza Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Avian Influenza Vaccines Market Drivers

The market drivers for the Avian Influenza Vaccines Market can be influenced by various factors. These may include:

Growing Incidence of Avian Influenza Outbreaks: One major factor driving the market is the increase in avian influenza outbreaks among poultry and birds around the world. The need for efficient vaccines is increasing as these epidemics endanger human and animal populations.

Government Initiatives and Regulations: To stop the spread of avian influenza, governments and international organisations are putting in place stringent laws and immunisation campaigns. These programmes foster an atmosphere that benefits vaccine producers and propels market expansion.

Expanding Poultry business: The need for avian influenza vaccinations is influenced by the growing poultry business, especially in emerging economies. Farmers are investing more in vaccination to protect their animals as a result of greater populations of chickens being at risk, which is supporting market growth.

Developments in Vaccine Technology: The safety and efficacy of avian influenza vaccinations are improved by continuous developments in vaccine technology, which include the creation of more effective and efficient vaccine formulations, delivery methods, and adjuvants. Through their ability to draw in both producers and consumers, these technical advancements promote market expansion.

Awareness and Education: A key factor in the expansion of the market is raising consumer, veterinarian, and poultry farmer knowledge of the value of vaccination in averting avian influenza epidemics. Higher vaccination uptake rates are a result of education efforts and information-dissemination programmes.

Globalisation and Trade: As poultry products are traded internationally, there is a greater chance that avian influenza will spread between countries. Global demand for avian influenza vaccines has increased as a result of numerous nations requiring vaccination programmes for chicken imports and exports in order to reduce risk and guarantee trade safety.

Global Avian Influenza Vaccines Market Restraints

Several factors can act as restraints or challenges for the Avian Influenza Vaccines Market. These may include:

High Expenses of Vaccine Development and Production: The market's ability to expand is hampered by the high expenses incurred in the study, creation, and manufacturing of avian influenza vaccinations. These costs may make vaccines more expensive for both manufacturers and recipients, especially in underdeveloped areas.

Limited Accessibility in Rural locations: The distribution and administration of avian influenza vaccines are hampered by accessibility concerns, particularly in rural or distant locations with poor healthcare facilities. This restriction lowers vaccination uptake and adds to the ongoing outbreaks in these areas.

Vaccine Safety and Efficacy Concerns: Despite improvements in vaccine technology, questions remain regarding the safety and efficacy of avian influenza vaccinations. The efficacy of vaccines, variations in virus strains, and possible side effects can all threaten public trust in immunisation campaigns and impede market expansion.

Regulatory Obstacles and Approval Procedures: Extensive regulatory specifications and drawn-out approval procedures for avian influenza vaccinations can cause delays in the release of new products and raise development expenses for producers. These legal obstacles prevent new competitors from entering the market, which reduces innovation and competition.

Global Economic Uncertainty: The demand for avian influenza vaccines can be impacted by changes in government healthcare budgets, consumer buying habits, and economic instability and volatility in international markets. Economic downturns may result in budget cuts to the agriculture and healthcare sectors, which would hinder the potential for market expansion.

Risk of Antigenic Drift and Vaccine Resistance: Vaccine efficacy is threatened by the ongoing development of avian influenza viruses due to antigenic drift. The advent of strains resistant to current vaccinations may make them less effective, requiring the time-consuming and expensive development of new formulations and approaches.

Global Avian Influenza Vaccines Market Segmentation Analysis

The Global Avian Influenza Vaccines Market is segmented on the basis of Type, Strain Type, Application, And Geography.

Avian Influenza Vaccines Market, By Type

  • Combination Vaccines
  • Inactivated Vaccines
  • Live Recombinant Vaccines

Based on Type, The market is classified into Combination vaccines, Inactivated vaccines, and Live recombinant vaccines.

Avian Influenza Vaccines Market, By Strain-Type

  • H5 Strain
  • H7 Strain
  • H9 Strain

Based on Strain-Type, The market is classified into is segmented by H5 strain, H7 strain, and H9 strain.

Avian Influenza Vaccines Market, By Application

  • Goose
  • Duck
  • Chicken
  • Others

Based on Application, The market is classified into is segmented by Goose, Duck, Chicken, and Others.

Avian Influenza Vaccines Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The market is classified into North America, Europe, Asia Pacific, and Rest of the world. APAC can keep ahead of the global Avian Influenza Vaccines Market growth curve. Increased avian influenza epidemics are to blame for the market's growth in the APAC region. Following the quick implementation of appropriate management strategies for avian influenza vaccine development, many government actions have been implemented to meet the emergent scenario. During the review period, the Avian Influenza Vaccines Market in Europe is expected to have the second-largest proportion of the global market. The surge in joint initiatives by regional governments and commercial entities to promote animal health could help to the market's growth.

Key Players

  • The major players in the Avian Influenza Vaccines Market are:
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • Zoetis Inc.
  • Ceva Sante Animale S.A.
  • Huvepharma, Inc.
  • Vencomatic Group B.V.
  • Aviva plc
  • Charles River Laboratories International, Inc.
  • Wuhan Biolake Biotechnology Co., Ltd.
  • Laboratorios HIPRA, S.A.QianYuanHao Biological Corporation Limite
  • Merial
  • Ringpu Bio-Technology Co. Ltd
  • Harbin Veterinary Research Institute (HVRI)
  • CEVA, Elanco, Zoetis, Inc.
  • FATRO S.p.A., Merck Animal Health (a subsidiary of Merck & Co. Inc.)
  • BoehringerIngelheim GmbH.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL AVIAN INFLUENZA VACCINES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL AVIAN INFLUENZA VACCINES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Combination Vaccines.
  • 5.3 Inactivated Vaccines
  • 5.4 Live Recombinant Vaccines

6 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY STRAIN-TYPE

  • 6.1 Overview
  • 6.2 H5 Strain
  • 6.3 H7 Strain
  • 6.4 H9 Strain

7 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Goose
  • 7.3 Duck
  • 7.4 Chicken
  • 7.5 Others

8 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL AVIAN INFLUENZA VACCINES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 QianYuanHao Biological Corporation Limited
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Merial
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Harbin Veterinary Research Institute (HVRI)
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CEVA
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Elanco
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 FATRO S.p.A.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Zoetis, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Ringpu Bio-Technology Co., Ltd
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merck Animal Health (a subsidiary of Merck & Co. Inc.)
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Boehringer Ingelheim GmbH
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research